全文获取类型
收费全文 | 1160811篇 |
免费 | 81142篇 |
国内免费 | 6340篇 |
专业分类
耳鼻咽喉 | 15939篇 |
儿科学 | 35628篇 |
妇产科学 | 30182篇 |
基础医学 | 165191篇 |
口腔科学 | 31753篇 |
临床医学 | 104376篇 |
内科学 | 218555篇 |
皮肤病学 | 25738篇 |
神经病学 | 86783篇 |
特种医学 | 45978篇 |
外国民族医学 | 227篇 |
外科学 | 173757篇 |
综合类 | 32916篇 |
现状与发展 | 17篇 |
一般理论 | 274篇 |
预防医学 | 80100篇 |
眼科学 | 26866篇 |
药学 | 94599篇 |
35篇 | |
中国医学 | 6232篇 |
肿瘤学 | 73147篇 |
出版年
2021年 | 10197篇 |
2019年 | 9682篇 |
2018年 | 13764篇 |
2017年 | 11041篇 |
2016年 | 12091篇 |
2015年 | 13999篇 |
2014年 | 18792篇 |
2013年 | 25642篇 |
2012年 | 35431篇 |
2011年 | 37423篇 |
2010年 | 22056篇 |
2009年 | 20534篇 |
2008年 | 33665篇 |
2007年 | 35917篇 |
2006年 | 36386篇 |
2005年 | 34278篇 |
2004年 | 32486篇 |
2003年 | 31454篇 |
2002年 | 30154篇 |
2001年 | 64945篇 |
2000年 | 66226篇 |
1999年 | 55388篇 |
1998年 | 14495篇 |
1997年 | 12663篇 |
1996年 | 12140篇 |
1995年 | 11309篇 |
1994年 | 10216篇 |
1993年 | 9458篇 |
1992年 | 39790篇 |
1991年 | 38022篇 |
1990年 | 37349篇 |
1989年 | 35784篇 |
1988年 | 32204篇 |
1987年 | 31184篇 |
1986年 | 29287篇 |
1985年 | 27324篇 |
1984年 | 19782篇 |
1983年 | 16568篇 |
1982年 | 9059篇 |
1979年 | 17300篇 |
1978年 | 11478篇 |
1977年 | 10288篇 |
1976年 | 8897篇 |
1975年 | 10127篇 |
1974年 | 11721篇 |
1973年 | 11363篇 |
1972年 | 10822篇 |
1971年 | 10154篇 |
1970年 | 9315篇 |
1969年 | 9002篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Hassen Lena M. Albarrak Rana A. Albahlal Reem A. Alsaqabi Dimah K. Hassen Ikhlass M. Daghestani Maha H. Alqurtas Eman M. Alkhalaf Abdulaziz T. Bedaiwi Mohammed K. Omair Mohammed A. Almaghlouth Ibrahim A. 《Quality of life research》2022,31(11):3229-3239
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional... 相似文献
3.
Molnár B. Aroca S. Dobos A. Orbán K. Szabó J. Windisch P. Stähli A. Sculean A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with... 相似文献
4.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献
5.
6.
7.
8.
9.
10.
Jesus K Yamamoto-Furusho Norma N Parra-Holgu n 《World journal of gastroenterology : WJG》2021,27(48):8242-8261
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years. 相似文献